A phase II trial of S-1 plus cisplatin with concurrent proton therapy for locally advanced NSCLC

A phase II trial of S-1 plus cisplatin with concurrent proton therapy for locally advanced NSCLC - A phase II trial of S-1 plus cisplatin with concurrent proton therapy for locally advanced NSCLC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000036978

Enrollment

Registered

2019-06-08

Start date

2013-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unresectable stage III NSCLC

Interventions

concurrent chemo-proton therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) histologically or cytologically-confirmed unresectable stage III NSCLC (2) chemo-naive status (3) ECOG-PS, 0-1 (4) age, 20-74 years old (5) no previous radiotherapy around the lesion (6) no previous chemotherapy (7) dose constraints of the organs at risk achievable (8) lesions evaluable with RECIST (9) written informed consent

Exclusion criteria

Exclusion criteria: (1)superior vena caval syndrome (2)Other cancers within 5 years (3)active and uncontrolled infection (4)Other serious complications (5)IP or IPF on X-p (6)pregnancy or lactation (7)portal vein tumor thrombosis (8)severe psychological disorders (9)malignant pleural effusion (10)uses fluoropyrimidine antineoplastic agent or flucytosine (11) cases in which the doctor is judged inappropriate for medical, psychological or other reasons other than the above (12)a coronary stent and aortic stent graft

Design outcomes

Primary

Measure	Time frame
2-year overall survival	—

Secondary

Measure	Time frame
acute and late toxicity,response rate, local control rate, median survival, progression free survival,change of quality of life (QOL)	—

Countries

Japan

Contacts

Public ContactHiromitsu Iwata

Nagoya City West Medical Center,Nagoya Proton Therapy Center Radiation oncology

h-iwa-ncu@nifty.com052-991-8577

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026